U.S. Pharma Stock News

If you are wondering whether Nutanix is a bargain or already pricing in its story, the key is to look closely at what you are paying for its future cash flows and growth potential. The stock last closed at US$40.32, with recent returns of 4.9% over 7 days, 0.5% over 30 days, a 20.3% decline year to date, and a 47.7% decline over 1 year. The 3 year and 5 year returns sit at 55.0% and 49.3% respectively. These mixed returns sit against a backdrop of ongoing interest in Nutanix's role in cloud...

In March 2026, indie Semiconductor completed a US$150,000,000 Rule 144A offering of 4.00% senior unsecured convertible notes due March 15, 2031, following its February 2026 report of continued annual net losses despite essentially flat year-over-year revenue. This combination of ongoing unprofitability and a new convertible debt layer raises fresh questions about the company’s capital structure, cash needs, and future dilution risk. We’ll now examine how this new US$150,000,000 convertible...

Archer Aviation (NYSE:ACHR) received full FAA acceptance of all Means of Compliance for its Midnight eVTOL aircraft, a first for the sector. The company also advanced commercial eVTOL certification in the UAE, marking a new step toward international air taxi operations. Archer is integrating NVIDIA's IGX Thor compute platform into its aircraft for advanced onboard autonomy capabilities. An industry first partnership with Starlink aims to equip Archer air taxis with satellite based...

In late February 2026, Block, Inc. reported full-year 2025 results showing revenue of US$24.19 billion and net income of US$1.31 billion, alongside a plan to cut more than 40% of its workforce with expected restructuring charges of US$450 million to US$500 million. The company framed these layoffs as part of an AI-enabled reshaping of its operations, aiming to boost efficiency and gross profit per employee even as headline earnings declined year on year. Next, we’ll examine how Block’s...

Abbott Laboratories context for investors Abbott Laboratories (ABT) has been trading with mixed recent returns, including a 0.4% decline over the past day, a 1.4% decline over the past week, a 3.4% gain over the past month, and a 9.8% decline over the past 3 months. See our latest analysis for Abbott Laboratories. At a share price of US$113.10, Abbott’s recent moves have been choppy, with a 1 year total shareholder return decline of 16.3% contrasting with a 3 year total shareholder return...

If you are wondering whether AGCO is still reasonably priced after its recent run, you are not alone. This article focuses on what the current share price might be implying about its value. AGCO’s share price recently closed at US$134.42, with returns of 0.4% over 7 days, 17.2% over 30 days, 27.0% year to date, and 48.3% over 1 year. These moves may have reshaped how the market views its potential and risk. Recent news coverage around AGCO has largely centered on its role in the capital...

In recent weeks, Unity Software reported fourth-quarter revenue of US$503.1 million, beating expectations and growing 10.1% year on year, but issued weaker EBITDA guidance that contrasted with the solid quarter. This mixed picture, alongside analyst concerns about AI-related risks, competitive pressures, and possible changes to its China operations, has prompted a broad reassessment of Unity’s business outlook. We’ll now examine how Unity’s strong recent results but softer guidance and...

In late February and early March 2026, Strategy Inc disclosed the purchase of 3,015 bitcoin for about US$204.1 million, lifting its holdings to roughly 720,737 BTC funded mainly through common and preferred equity issuance. At the same time, Strategy raised the dividend on its variable-rate STRC preferred shares to 11.5%, highlighting its growing reliance on this high-yield “digital credit” instrument to finance ongoing bitcoin accumulation. We’ll now examine how this renewed bitcoin buying,...

BillionToOne: recent moves in context BillionToOne (BLLN) has drawn attention after recent trading left the stock with a 2.8% one day decline, a 13.2% gain over the past week, and a 27.6% loss over the past 3 months. See our latest analysis for BillionToOne. At a recent share price of US$80.83, BillionToOne’s short-term momentum, shown by a 13.2% 7-day share price return, contrasts with weaker recent months, as the 90-day share price return of a 27.6% decline points to fading longer-term...

How KB Home stock has been performing KB Home (KBH) has drawn investor attention after a mixed set of recent performance metrics, with short term price moves contrasting with longer term returns and modest changes in its reported revenue and net income. Over the past day and week, KBH has seen share price declines of 1.3% and 5.3%. The stock shows a gain over the past month and a negative total return over the past year. Looking further back, KBH reports a total return of about 75% over the...

SPX Technologies (SPXC) shares drew fresh attention after the company reported a strong fourth quarter and full year 2025 earnings, issued new 2026 revenue guidance, and disclosed a small intangible asset impairment. See our latest analysis for SPX Technologies. At a share price of $222.07, SPX Technologies has logged a 9.25% year to date share price return, with a 57.46% total shareholder return over the past year and a 280.39% total shareholder return over five years. This suggests that...

In recent days, ESCO Technologies reported very large sales growth and a jump in orders in its Aerospace & Defense segment, lifting its order backlog and revenue visibility. This surge in defense-related demand reinforces earlier assessments of ESCO as a quality-focused industrial with strong returns on invested capital and a solid balance sheet. We’ll now examine how this Aerospace & Defense backlog strength may reshape ESCO Technologies’ existing investment narrative and risk-reward...

Apellis Pharmaceuticals (NasdaqGS:APLS) has appointed Dr. Mikael Dolsten to its board of directors. Dr. Dolsten is a former chief scientific officer at Pfizer with extensive experience in pharmaceutical R&D and drug approvals. The appointment adds long tenured large pharma leadership to Apellis' governance and scientific oversight. Apellis focuses on therapies that target the complement system, a part of the immune system that plays a role in several serious diseases. For investors watching...

Freshworks (FRSH) has moved into focus after unveiling a US$400 million share repurchase plan along with a CEO share purchase, following a recent month long 25% slide in the stock price. See our latest analysis for Freshworks. Those buyback and insider purchase headlines arrived after a difficult stretch, with a 30 day share price return of a 20.54% decline and a 1 year total shareholder return of a 49.07% decline. However, recent 7 day and 1 day share price returns suggest short term...

Addus HomeCare Corporation reported past fourth-quarter 2025 net income of US$29.78 million and full-year net income of US$95.91 million, with diluted earnings per share from continuing operations rising to US$1.61 for the quarter and US$5.22 for the year compared with the prior year. Alongside this stronger profitability, management signaled plans to pursue selective 2026 acquisitions supported by its current capital structure, while also engaging investors at the Raymond James...

Japan reimbursement approval reshapes Optune Lua access NovoCure (NVCR) just received reimbursement approval in Japan for its Optune Lua device through the National Health Insurance, a regulatory milestone that widens access for eligible non small cell lung cancer patients. For you as an investor, this decision ties product adoption directly to a large, insurance backed market. It adds a fresh piece of information to weigh against NovoCure's existing financial profile and share price...

Antero Resources (NYSE:AR) has completed the sale of substantially all of its Utica Shale oil and gas assets. The company is using the proceeds to retire senior notes and reduce debt, reshaping its balance sheet. This portfolio shift marks a refocus of the business toward its remaining core assets. Antero Resources, trading at $37.79, is making this move after a stretch of strong multi year returns, including 50.3% over 3 years and a very large gain over 5 years. Shorter term, the stock is...

Erie Indemnity recently reported full-year 2025 results, with revenue rising to US$4,067.26 million while net income eased to US$559.34 million and diluted EPS from continuing operations slipped to US$10.69. A key nuance for investors is that earnings were affected by a US$100 million pre-tax charitable contribution in the fourth quarter, alongside news that long-serving CEO Tim NeCastro plans to retire at the end of 2026. Next, we’ll examine how the EPS beat despite softer full-year profit...

In late February 2026, Synopsys reported first-quarter revenue of US$2,408.8 million and net income of US$64.96 million, raised its full-year GAAP EPS guidance, and approved an additional US$2,000 million share repurchase authorization alongside a new US$250 million accelerated buyback program. Away from the headline numbers, Synopsys also deepened its reach into cutting-edge edge-AI design by supporting Innatera’s neuromorphic microcontrollers with its PathFinder-SC and Totem reliability...

Why TETRA Technologies is back in focus after a record 2025 TETRA Technologies (TTI) is on investors radar after reporting a record 2025, supported by strong offshore completion fluids activity, improved adjusted EBITDA margins, and plans to scale key projects across Arkansas, Argentina, and desalination. See our latest analysis for TETRA Technologies. The latest record-year update and expansion plans have come alongside a share price of US$8.60 and a sharp 30 day share price return of...

Brinker International (NYSE:EAT) has promoted George Felix to Executive Vice President and Chief Marketing Officer. Felix will oversee brand strategy for Chili's Grill & Bar and Maggiano's Little Italy. His expanded remit includes launching a "Back to Maggiano's" plan aimed at revitalizing the Maggiano's brand. For investors watching Brinker International at a share price of $137.94, this move places a well known internal marketing leader at the center of both Chili's and Maggiano's. The...

Magnite and Genius Sports have introduced a real-time live sports advertising integration for premium CTV and digital inventory. The integration uses Genius Sports' Moment Engine to feed verified, real-time sports signals into Magnite's ClearLine platform. Advertisers can align campaigns with live in-game moments, targeting high engagement windows for fans across connected TV and digital channels. For investors watching NasdaqGS:MGNI, this update sits against a mixed share price backdrop...

Upcoming earnings as a key catalyst Gevo (GEVO) heads into its quarterly earnings release on March 5, 2026, with the market focused on an expected earnings per share of a US$0.03 loss and any forward guidance management provides. See our latest analysis for Gevo. Gevo’s recent share price return shows a mixed picture, with a 1 day gain of 2.69% and a 7 day rise of 4.37% contrasting with a 90 day share price return decline of 19.41%. The 1 year total shareholder return of 44.70% hints at...

Key snapshot of Amplitude’s recent share performance Amplitude (AMPL) has been moving around recently, with the share price at $7.72 after a 1 day return of 1.85%. Over the past week, the stock shows a 15.92% gain. Those shorter term moves sit against weaker recent trends, with a month return of 14.79% and a past 3 months return of 29.75%, alongside a year to date return of 29.37% and a 1 year total return of 39.50%. See our latest analysis for Amplitude. Putting it together, Amplitude’s...